Gill Heart and Vascular Institute and Division of Cardiovascular Medicine, University of Kentucky and The Lexington VA Medical Center, Lexington, KY 40508, USA.
Int J Mol Sci. 2021 Jan 26;22(3):1201. doi: 10.3390/ijms22031201.
Stem cell-based cardiac therapies have been extensively studied in recent years. However, the efficacy of cell delivery, engraftment, and differentiation post-transplant remain continuous challenges and represent opportunities to further refine our current strategies. Despite limited long-term cardiac retention, stem cell treatment leads to sustained cardiac benefit following myocardial infarction (MI). This review summarizes the current knowledge on stem cell based cardiac immunomodulation by highlighting the cellular and molecular mechanisms of different immune responses to mesenchymal stem cells (MSCs) and their secretory factors. This review also addresses the clinical evidence in the field.
近年来，基于干细胞的心脏治疗方法受到了广泛的研究。然而，细胞移植后的输送、植入和分化效果仍然是持续存在的挑战，这也为进一步完善我们现有的策略提供了机会。尽管心脏的长期保留效果有限，但干细胞治疗仍能在心肌梗死（MI）后带来持续的心脏益处。本综述通过强调间充质干细胞（MSCs）及其分泌因子的不同免疫反应的细胞和分子机制，总结了基于干细胞的心脏免疫调节的现有知识。本综述还讨论了该领域的临床证据。
